Growth of Kym-1 rhabdomyosarcoma cells depends on endogenous receptor tyrosine kinase signals activated by insulin and insulin-like growth factors (IGF), as revealed from enhancement of ...

and insulin receptor (InsR). However, it is unknown whether and how mTOR regulates IGF-IR and InsR themselves. Here we show that mTOR possesses unexpected tyrosine kinase activity and activates ...

Some examples include the epidermal growth factor receptor, platelet-derived growth factor receptor, and insulin receptor. Activation of intracellular tyrosine kinase by these growth factors ...

Activated PKCε binds to and inhibits the insulin receptor tyrosine kinase, leading to decreased insulin-stimulated glycogen synthesis in the liver owing to decreased phosphorylation of GSK3.

Background: OSI-906 is a potent inhibitor of IGF-1R and IR tyrosine kinase activity. Increased IGF-1R activity is observed in human malignancies and implicated in resistance to chemotherapy. Methods: ...

Tyrosine kinase inhibitors, such as gefitinib (Iressa ™, ZD1839), block the EGFR. As a result, there is inhibition of cellular proliferation, promotion of apoptosis, and inhibition of anti ...

"Our study showed that targeting TYK2 could be a powerful way to protect insulin-producing beta ... Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays ...

Emerging treatments like tyrosine kinase inhibitors (TKIs) offer promise by targeting complementary pathways in angiogenesis and providing sustained-release options to reduce injection frequency.

type 2 diabetes or cardiovascular disease, among others. Recent findings have suggested that EphB tyrosine kinase receptor and its ligand, ephrin B, may be involved in insulin signaling.

Using human endothelial cells, they found that ADM inhibited insulin receptor phosphorylation via protein-tyrosine phosphatase ... cAMP and activates protein kinase A (PKA). PKA then ...

Protein kinase inhibitors can be subdivided according to the amino acid on a protein that they add the phosphate to (e.g serine, threonine or tyrosine) in order to inhibit phosphorylation of that ...

Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors.